BNS

Decomposing systemic risk: the roles of contagion and common exposures

Retrieved on: 
Martedì, Aprile 23, 2024
Tao, CIBC, Tax, RWA, Risk, European Systemic Risk Board, Research Papers in Economics, Contagion, RT, The Big Six, NBC, International, Shock, Observation, Bank of Canada, HTC, European Economic Association, The Washington Post, Great, JPMorgan Chase, Paper, GM, Environment, Political economy, Journal of Financial Economics, COVID-19, Perception, BNS, Website, Silicon, IAT, Cifuentes, Probability, Balance sheet, RAN, Medical classification, Algorithm, Information technology, Quarterly Journal of Economics, LN, Nature, European Journal, Royal Bank of Canada, Technical report, Journal of Political Economy, Equitable Bank, Bankruptcy, RAI, PDF, Private, ECB, Policy, CHS, Supercapacitor, Social science, Journal of Financial Stability, Intelligence (journal), Elsevier, Home, Cambridge University Press, Journal, Springer Science+Business Media, Research, Classification, Regulation, News, EQB, Credit, Literature, AIK, European Central Bank, COVID, SVAR, Section 5, Management science, DRA, M4, VL, National bank, Government, ISSN, BMO, Panel, International Financial Reporting Standards, BIS, FIS, Basel III, Commerce, Scotiabank, C32, Econometric Society, Interbank, Fraud, Section 4, Bank, Schedule, VAR, Section 3, The Journal of Finance, RBC, Volcanic explosivity index, Fire, Wassily Leontief, Financial economics, Metric, Section 2, L14, Central bank, Superintendent, Bank of Montreal, Kronecker, BOC, Lithium, BCBS, Sale, Macroeconomic Dynamics, Christophe, CWB, LBC, NHA, Imperial Bank, Private equity, Quarterly Journal, National Bank of Canada, C51, Canadian Western Bank, Currency crisis, JEL classification codes, Victor Drai, L.1, MFC, Silicon Valley Bank, EB, Laurentian Bank of Canada, Federal, RA1, Series, W0, FEVD, Journal of Econometrics, Aggregate, University, FRB, MB, Financial institution, Element, Health, Book, Angels & Airwaves, Common, OSFI, GFC, Reproduction, K L, Systematic, Housing, G21, Home Capital Group, Communications satellite

Abstract

Key Points: 
    • Abstract
      We evaluate the effects of contagion and common exposure on banks? capital through
      a regression design inspired by the structural VAR literature and derived from the balance
      sheet identity.
    • Contagion can occur through direct exposures, fire sales, and market-based
      sentiment, while common exposures result from portfolio overlaps.
    • First, we document that contagion varies in time, with the highest levels
      around the Great Financial Crisis and lowest levels during the pandemic.
    • Our new framework complements
      traditional stress-tests focused on single institutions by providing a holistic view of systemic risk.
    • While existing literature presents various contagion narratives, empirical findings on
      distress propagation - a precursor to defaults - remain scarce.
    • We decompose systemic risk into three elements: contagion, common exposures, and idiosyncratic risk, all derived from banks? balance sheet identities.
    • The contagion factor encompasses both sentiment- and contractual-based elements, common exposures consider systemic
      aspects, while idiosyncratic risk encapsulates unique bank-specific risk sources.
    • Our empirical analysis of the Canadian banking system reveals the dynamic nature of contagion, with elevated levels observed during the Global Financial Crisis.
    • In conclusion, our model offers a comprehensive lens for policy intervention analysis and
      scenario evaluations on contagion and systemic risk in banking.
    • This
      notion of systemic risk implies two key components: first, systematic risks (e.g., risks related
      to common exposures) and second, contagion (i.e., an initially idiosyncratic problem becoming
      more widespread throughout the financial system) (see Caruana, 2010).
    • In this paper, we decompose systemic risk into three components: contagion, common exposures, and idiosyncratic risk.
    • First, we include contagion in three forms: sentiment-based contagion, contractual-based
      contagion, and price-mediated contagion.
    • In this context,
      portfolio overlaps create common exposures, implying that bigger overlaps make systematic
      shocks more systemic.
    • With the COVID-19 pandemic starting
      in 2020, contagion drops to all time lows, potentially related to strong fiscal and monetary
      supports.
    • That is, our
      structural model provides a framework for analyzing the impact of policy interventions and
      scenarios on different levels of contagion and systemic risk in the banking system.
    • This provides a complementary approach to
      seminal papers that took a structural approach to contagion, such as DebtRank Battiston et al.
    • More generally, the literature on networks and systemic risk started with Allen and Gale
      (2001) and Eisenberg and Noe (2001).
    • The matrix is structured as follows:
      1

      In our model, we do not distinguish between interbank liabilities and other types of liabilities.

    • In other words, we can and aim to estimate different degrees
      of contagion per asset class, i.e., potentially distinct parameters ?Ga .
    • For that, we build three major
      metrics to check: average contagion, average common exposure, and average idiosyncratic risk.
    • N i j

      et ,
      Further, we define the (N ?K) common exposure matrix as Commt = [A

      (20)

      et ]diag (?C
      ?L

      such that average common exposure reads,
      average common exposure =

      1 XX
      Commik,t .

    • N i j

      (22)

      20

      ? c ),

      The three metrics?average contagion, average common exposure, and average idiosyncratic risk?provide a comprehensive framework for understanding banking dynamics.

    • Figure 4 depicts the average level of risks per systemic risk channel: contagion risk, common exposure, and idiosyncratic risk.
    • Figure 4: Average levels of contagion (Equation (20)), common exposure (Equation (21)), and idiosyncratic risk
      (Equation (22)).
    • The market-based contagion is the contagion due to
      investors? sentiment, and the network is an estimate FEVD on volatility data.
    • For most of
      the sample, we find that contagion had a bigger impact on the variance than common exposures.

S Split Corp. Announces Year End Results

Retrieved on: 
Mercoledì, Marzo 27, 2024

TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. (the “Fund”) announces results of operations for the year ended December 31, 2023.

Key Points: 
  • TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. (the “Fund”) announces results of operations for the year ended December 31, 2023.
  • Decrease in net assets attributable to holders of Class A shares amounted to $0.36 million or $0.81 per Class A share.
  • As at December 31, 2023, net assets attributable to holders of Class A shares were $0.94 million or $2.28 per Class A share.
  • The Fund’s Preferred and Class A shares are listed on Toronto Stock Exchange under the symbols SBN.PR.A and SBN respectively.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Mercoledì, Marzo 27, 2024

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Retrieved on: 
Lunedì, Gennaio 22, 2024

“Attainment of complete CNS clearance in a patient with Bing-Neel Syndrome after previous exposure to BTKi therapy is encouraging,” commented Jorge Castillo, M.D., associate professor at Harvard Medical School and director of Bing Center Clinic at Dana Farber Cancer Institute.

Key Points: 
  • “Attainment of complete CNS clearance in a patient with Bing-Neel Syndrome after previous exposure to BTKi therapy is encouraging,” commented Jorge Castillo, M.D., associate professor at Harvard Medical School and director of Bing Center Clinic at Dana Farber Cancer Institute.
  • Cerebrospinal fluid flow cytometry showed no evidence of clonal B-cells, and molecular analysis did not detect the MYD88 mutation.
  • This very encouraging patient response further supports iopofosine’s development in CNS-related malignancies, including CNS lymphoma and pediatric high-grade gliomas.”
    Cellectar previously announced a complete response in a patient with relapsed/refractory primary central nervous system lymphoma (CNSL) as part of its ongoing Phase 2a trial of iopofosine I 131.
  • The study objective is to identify the recommended iopofosine I 131 Phase 2 dose in pHGG patients.

S Split Corp. Announces Semi-Annual Results

Retrieved on: 
Martedì, Agosto 29, 2023

TORONTO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. announces results of operations for the six months ended June 30, 2023.

Key Points: 
  • TORONTO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. announces results of operations for the six months ended June 30, 2023.
  • Decrease in net assets attributable to holders of Class A shares amounted to $0.74 million or $0.17 per Class A share.
  • Net assets attributable to holders of Class A shares as at June 30, 2023 were $1.29 million or $2.86 per Class A share.
  • The Fund’s Class A and Preferred shares are listed on Toronto Stock Exchange under the symbols SBN and SBN.PR.A respectively.

WEMIX Announces Listing on Indian Cryptocurrency Exchange CoinDCX

Retrieved on: 
Lunedì, Luglio 24, 2023

CoinDCX was rated “Best for Advanced Crypto Traders'' and the overall number one ranking in Forbes Advisor India’s recently published list of the “ Best Cryptocurrency Exchanges Of 2023 ”.

Key Points: 
  • CoinDCX was rated “Best for Advanced Crypto Traders'' and the overall number one ranking in Forbes Advisor India’s recently published list of the “ Best Cryptocurrency Exchanges Of 2023 ”.
  • CoinDCX is the second Indian exchange listing for WEMIX following the February listing on BNS (formerly known as BitBNS), India's largest virtual asset exchange, marking the continued expansion of the WEMIX ecosystem in India.
  • With over 4 million users, BNS has become synonymous for introducing metaverse tokens to Indian crypto investors after successfully listing popular metaverse tokens in the past two years.
  • Visit the WEMIX PLAY official website: ( wemixplay.com ) and CoinDCX blog ( https://coindcx.com/blog/listings/what-is-wemix/) for more information.

BNS Ophthalmics appoints Joseph Papa and Ari Kellen to the Board of Directors

Retrieved on: 
Mercoledì, Giugno 21, 2023

ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.

Key Points: 
  • ATHENS, Greece, June 21, 2023 /PRNewswire/ -- BNS Ophthalmics (BNSO) is pleased to announce the appointments of Joseph Papa and Ari Kellen to the Board of Directors.
  • Joseph and Ari, having worked together, bring an impressive and successful track record of leadership and achievements.
  • The presence of Joseph and Ari in the BNSO Board reflects their confidence in BNSO scientific potential and excitement about the future prospects of BNSO.
  • Aris Mitsopoulos, Vice President of RAFARM and CEO of BNSO, stated: "We are thrilled to welcome Joseph Papa and Ari Kellen, to our esteemed Board of Directors.

ZETRIX DEPLOYS W3C-COMPLIANT DIGITAL IDENTITY SERVICE ('DIS') AS XINGHUO INTERNATIONAL SUPERNODE GOES LIVE

Retrieved on: 
Venerdì, Giugno 2, 2023

PETALING JAYA, Malaysia, June 1, 2023 /PRNewswire/ -- Zetrix, the Layer-1 blockchain platform by MY E.G. Services Berhad ("MYEG"), today announced the successful live deployment of the Xinghuo International Super Node along with the introduction of groundbreaking Xinghuo BIF naming services namely Xinghuo Beta Name System ("BNS")  and Xinghuo Digital Identity Service, which are fully compliant with W3C International Standards.

Key Points: 
  • Services Berhad ("MYEG"), today announced the successful live deployment of the Xinghuo International Super Node along with the introduction of groundbreaking Xinghuo BIF naming services namely Xinghuo Beta Name System ("BNS")  and Xinghuo Digital Identity Service, which are fully compliant with W3C International Standards.
  • The World Wide Web Consortium ("W3C") is an international community that develops open standards to ensure the long-term growth of the Web.
  • Complying with the latest W3C standards, the Xinghuo Digital Identity Service is a pioneering decentralised identity service that enables immutable verification of online identities.
  • Through the Xinghuo International Super Node, operated by Zetrix, on-chain assets and transactions can now cross seamlessly across the Zetrix and Xinghuo blockchains, thus connecting governments, businesses, and individuals to a global blockchain-based ecosystem.

ZETRIX DEPLOYS W3C-COMPLIANT DIGITAL IDENTITY SERVICE ('DIS') AS XINGHUO INTERNATIONAL SUPERNODE GOES LIVE

Retrieved on: 
Venerdì, Giugno 2, 2023

PETALING JAYA, Malaysia, June 2, 2023 /PRNewswire/ -- Zetrix, the Layer-1 blockchain platform by MY E.G. Services Berhad ("MYEG"), today announced the successful live deployment of the Xinghuo International Super Node along with the introduction of groundbreaking Xinghuo BIF naming services namely Xinghuo Beta Name System ("BNS")  and Xinghuo Digital Identity Service, which are fully compliant with W3C International Standards.

Key Points: 
  • Services Berhad ("MYEG"), today announced the successful live deployment of the Xinghuo International Super Node along with the introduction of groundbreaking Xinghuo BIF naming services namely Xinghuo Beta Name System ("BNS")  and Xinghuo Digital Identity Service, which are fully compliant with W3C International Standards.
  • The World Wide Web Consortium ("W3C") is an international community that develops open standards to ensure the long-term growth of the Web.
  • Complying with the latest W3C standards, the Xinghuo Digital Identity Service is a pioneering decentralised identity service that enables immutable verification of online identities.
  • Through the Xinghuo International Super Node, operated by Zetrix, on-chain assets and transactions can now cross seamlessly across the Zetrix and Xinghuo blockchains, thus connecting governments, businesses, and individuals to a global blockchain-based ecosystem.

BNS and RAFARM create BNS Ophthalmics to leverage nanotechnology in the development of novel ophthalmic products

Retrieved on: 
Martedì, Maggio 30, 2023

BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.

Key Points: 
  • BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.
  • BNS will contribute its intellectual property and R&D expertise to BNSO while Rafarm will provide appropriate funding, together with infrastructure for development, commercial scale manufacturing, and distribution.
  • Our collaboration with BNS, whom we recognize as a leader in the field of nanotechnology, marks a significant milestone of RAFARM in innovative technologies.
  • We join forces with BNS for the development and production of novel therapeutic products and to further expand our expertise in ophthalmics."